- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: ACY-241 | Compound (I) [WO2016200919]  | HDAC-IN-2
Compound class: Synthetic organic
Comment: Citarinostat (ACY-241) is a next-generation HDAC6 inhibitor, that is under investigation for potential antineoplastic activity . Note that it exhibits only ~10-fold enzymic selectivity against the class I isoform, HDAC1.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Huang P, Almeciga-Pinto I, Jarpe M, van Duzer JH, Mazitschek R, Yang M, Jones SS, Quayle SN. (2017)
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.
Oncotarget, 8 (2): 2694-2707. [PMID:27926524]
2. Van DJH, Seyedi F, Liu G. (2016)
Crystalline forms of a histone deacetylase inhibitor.
Patent number: WO2016200919. Assignee: Acetylon Pharmaceuticals, Inc.. Priority date: 08/06/2015. Publication date: 15/12/2016.